An observational study in Prostate Cancer, sponsored by TSH Biopharm Corporation Limited. Status unknown at 1 site in Taiwan. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2022-01-06.
Sponsored by TSH Biopharm Corporation Limited · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Prostatic Neoplasms with a site in Taiwan — 28 open to participants now, 55 under way, 29 of them phase 3. Prostatic Neoplasms · Taiwan.
Among the 127 studies in Prostatic Neoplasms with a site in Taiwan, this one is the 14th largest by planned enrollment of the 24 observational ones that give a count, is one of 7 that started in 2021, is one of 24 observational ones, and was the 88th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →28 of the 127 studies in Prostatic Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Taiwan, United States, Austria and 18 more countries
Ages 18+ · Men only
AstraZeneca · Sites in Taiwan, United States, Australia and 21 more countries
Ages 18+ · Men only
National Taiwan University Hospital · Sites in Taiwan
Ages 20+ · Men only
Novartis Pharmaceuticals · Sites in Taiwan, United States, Canada and 8 more countries
Ages 18+
Amgen · Sites in Taiwan, United States, Australia and 15 more countries
Ages 18+ · Men only
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 45 Years and older · male.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 17 · Phase 3 59 · Phase 4 3
First in 2002; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 200 across 1,311 observational studies indexed under Prostatic Neoplasms.
Median enrollment 662 across the 102 interventional studies, 226 across the 24 observational. Of the 55 that completed or were terminated, 36 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 127 have an industry lead sponsor. The 10 most frequent:
TSH Biopharm Corporation Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.
TSH Biopharm Corporation Limited has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
18 of the studies in Prostatic Neoplasms with a site in Taiwan that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 127 studies in Prostatic Neoplasms with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the diagnostic accuracy of the Mitomic Prostate Test (MPT) comparing to prostate biopsy within the intended use population.
To determine the clinical performance of a blood-based test for clinically significant (CS) prostate cancer (PCa) (grade group ≥ 2) intended for use in men with prostate serum antigen levels in the 'grey zone' (PSA \< 10 ng/ml). The test quantifies a previously described 3.4 kb mitochondrial DNA (mtDNA) deletion.
To investigate the mitochondrial DNA biomarker in a large group of patients suspicious for prostate cancer to evaluate the Mitomic Prostate Test (MPT)'s accuracy in target population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mitomic Prostate Test
Mitomic Prostate Test (MPT)
To evaluate the diagnostic accuracy of the Mitomic Prostate Test (MPT) within the intended use population.
Time frame: 16 weeks
MPT compared to the current standard of care (SOC).
To evaluate optimal disease screening strategies incorporating MPT compared to the current standard of care (SOC).
Time frame: 16 weeks
Started Apr 2021 (actual). Primary completion is estimated for Dec 2022, 20 months after the start.
Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 20 months is below that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 29 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TSH Biopharm Corporation Limited